个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

A Phase 2 Study of Anlotinib Combined with Pemetrexed-Platinum (PP) as Second-Line Treatment in EGFR-Positive Non-Small Cell Lung Cancer (NSCLC)

| 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Li, J.[1] * ; Ge, J.[1] ; Tian, Y.[1] ; Yang, Y.[1] ; Zheng, M.[1] ; Yu, P.[1] ; Yao, W.[1] ;
机构： [1]Sichuan Cancer Hospital & Institute, Chengdu/CN
出处：
ISSN：

关键词： Anlotinib Second-line therapy EGFR-mutant NSCLC

语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2021]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2021]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]Sichuan Cancer Hospital & Institute, Chengdu/CN
推荐引用方式(GB/T 7714)：
Li J.,Ge J.,Tian Y.,et al.A Phase 2 Study of Anlotinib Combined with Pemetrexed-Platinum (PP) as Second-Line Treatment in EGFR-Positive Non-Small Cell Lung Cancer (NSCLC)[J].JOURNAL OF THORACIC ONCOLOGY.2021,16(3):S602-S602.
APA：
Li, J.,Ge, J.,Tian, Y.,Yang, Y.,Zheng, M....&Yao, W..(2021).A Phase 2 Study of Anlotinib Combined with Pemetrexed-Platinum (PP) as Second-Line Treatment in EGFR-Positive Non-Small Cell Lung Cancer (NSCLC).JOURNAL OF THORACIC ONCOLOGY,16,(3)
MLA：
Li, J.,et al."A Phase 2 Study of Anlotinib Combined with Pemetrexed-Platinum (PP) as Second-Line Treatment in EGFR-Positive Non-Small Cell Lung Cancer (NSCLC)".JOURNAL OF THORACIC ONCOLOGY 16..3(2021):S602-S602

相关文献

[1]First-Line Management of EGFR Mutant NSCLC [2]Structure-based classification predicts drug response in EGFR-mutant NSCLC. [3]Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC. [4]The novel BET degrader, QCA570, is highly active against the growth of human NSCLC cells and synergizes with osimertinib in suppressing osimertinib-resistant EGFR-mutant NSCLC cells. [5]Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma. [6]A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer [7]Efficacy and Safety of Erlotinib vs Vinorelbine/Cisplatin as Adjuvant Therapy for Stage IIIA EGFR Mutant NSCLC Patients [8]Efficacy and Safety of Erlotinib vs Vinorelbine/Cisplatin as Adjuvant Therapy for Stage IIIA EGFR Mutant NSCLC Patients [9]OSIMERTINIB AS FIRST-LINE AND SECOND-LINE THERAPY FOR EGFR MUTATION-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS IN CHINA [10]Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase 3 MARIPOSA-2 study

资源点击量：52808 今日访问量：1 总访问量：4560 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号